Initial Management of Atrial Fibrillation

Immediate Assessment and Management

The American College of Cardiology recommends assessing for signs of instability including hypotension, ongoing chest pain/ischemia, altered mental status, shock, or pulmonary edema in patients with atrial fibrillation 1
If hemodynamically unstable, the American College of Cardiology suggests performing immediate direct-current cardioversion without delay for anticoagulation 1
Administer heparin concurrently with cardioversion if AF duration exceeds 48 hours or is unknown, as recommended by the American College of Cardiology 1
Document AF with at least a single-lead ECG recording during the arrhythmia to establish the diagnosis before initiating treatment, according to the American Heart Association 2
Assess the ventricular rate, QRS duration, and QT interval on the ECG, as recommended by the American Heart Association 2

For patients with left ventricular ejection fraction (LVEF) >40%, the American College of Cardiology recommends administering intravenous beta-blockers (metoprolol preferred) or non-dihydropyridine calcium channel blockers (diltiazem or verapamil) as first-line therapy 3
Target initial heart rate <110 beats per minute (lenient rate control), as suggested by the European Society of Cardiology 4
Metoprolol: 2.5-5 mg IV bolus over 2 minutes, repeat every 5-10 minutes up to 15 mg total, according to the American College of Cardiology 5
Diltiazem: 0.25 mg/kg IV bolus over 2 minutes, followed by 0.35 mg/kg if needed, then continuous infusion 5-15 mg/hour, as recommended by the American College of Cardiology 5

Initiate anticoagulation for all eligible patients with CHA₂DS₂-VASc score ≥2 (or consider for score of 1), as recommended by the European Society of Cardiology 6
Calculate CHA₂DS₂-VASc score, which includes components such as congestive heart failure, hypertension, age, diabetes, stroke/TIA/thromboembolism history, vascular disease, age, and sex category, according to the European Society of Cardiology 6
Prescribe direct oral anticoagulants (DOACs)—apixaban, dabigatran, edoxaban, or rivaroxaban—over warfarin except in patients with mechanical heart valves or mitral stenosis, as recommended by the European Society of Cardiology 6

Obtain transthoracic echocardiogram to assess left atrial size, left ventricular function, valvular disease, and exclude structural abnormalities, as recommended by the American Heart Association 2
Order blood tests for thyroid function (TSH), renal function (creatinine clearance), hepatic function, and electrolytes, according to the American Heart Association 2

Consider rhythm control for symptomatic patients, younger patients, or those with new-onset AF (<48 hours), as suggested by the American College of Cardiology 3
Provide therapeutic anticoagulation for 3 weeks before elective cardioversion for AF duration >48 hours or unknown duration, according to the American College of Cardiology 1
Continue anticoagulation for at least 4 weeks after cardioversion, as recommended by the American College of Cardiology 1

Do not use digoxin as sole agent for rate control in paroxysmal AF—it is ineffective during exercise and sympathetic surge, as warned by the American College of Cardiology 1
Do not delay cardioversion for anticoagulation in truly unstable patients—hemodynamic instability takes precedence, according to the American College of Cardiology 1
Do not combine anticoagulants with antiplatelet agents unless acute vascular event or specific procedural indication—increases bleeding risk without additional benefit, as cautioned by the European Society of Cardiology 6

The American College of Cardiology recommends proceeding directly to synchronized electrical cardioversion at 120-200 joules biphasic (or 200 joules monophasic) under appropriate sedation for hemodynamically unstable patients, and administer intravenous unfractionated heparin bolus followed by continuous infusion concurrently, with a strength of evidence based on expert opinion 7

The European Heart Journal guidelines state that congestive heart failure is assigned 1 point in the CHA₂DS₂-VASc score, which is used to assess stroke risk in patients with atrial fibrillation, with a strength of evidence based on high-quality studies 8
The European Heart Journal guidelines also state that age ≥75 years is assigned 2 points, diabetes mellitus is assigned 1 point, and age 65-74 years is assigned 1 point in the CHA₂DS₂-VASc score, with a strength of evidence based on high-quality studies 9
The European Heart Journal recommends initiating anticoagulation for all patients with a CHA₂DS₂-VASc score ≥2, with a strength of evidence based on high-quality studies 8

The European Heart Journal guidelines state that for atrial fibrillation duration <48 hours, cardioversion may proceed after initiating anticoagulation without waiting for therapeutic levels, with a strength of evidence based on moderate-quality studies 10
The American College of Cardiology recommends providing therapeutic anticoagulation for 3 weeks before elective cardioversion for atrial fibrillation duration >48 hours or unknown duration, then continuing anticoagulation for a minimum of 4 weeks after cardioversion, with a strength of evidence based on high-quality studies 7

The European Heart Journal guidelines suggest considering early rhythm control for younger patients (<65 years) and patients with heart failure with reduced ejection fraction (HFrEF), with a strength of evidence based on moderate-quality studies 9